In contrast, in chronic myeloid leukaemia (CML), this treatment was able to reverse the effects of drug resistance by downregulating the expression of P-glycoprotein (P-gp) and S100A8 and increasing doxorubicin-induced apoptosis [86]. Here, ABCB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.